BioNTech SE Reports Q3 2025 Results
Ticker: BNTX · Form: 6-K · Filed: Nov 3, 2025 · CIK: 1776985
| Field | Detail |
|---|---|
| Company | Biontech Se (BNTX) |
| Form Type | 6-K |
| Filed Date | Nov 3, 2025 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: earnings, financial-results, corporate-update
TL;DR
BioNTech dropped Q3 earnings report Nov 3rd.
AI Summary
BioNTech SE announced its third quarter 2025 financial results and corporate update on November 3, 2025. The company is a German biotechnology firm headquartered in Mainz.
Why It Matters
This filing provides investors with the latest financial performance and strategic updates from BioNTech SE, a key player in the biotechnology sector.
Risk Assessment
Risk Level: low — This is a routine financial results filing with no immediate material events indicated.
Key Players & Entities
- BioNTech SE (company) — Registrant
- November 3, 2025 (date) — Filing date and announcement date
FAQ
What is the filing type and submission date?
This is a Form 6-K filed on November 3, 2025.
What is the company's full name and headquarters?
The company's full name is BioNTech SE, and it is headquartered in Mainz, Germany.
What is the purpose of this Form 6-K?
This Form 6-K is a report of a foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934, including a press release announcing third quarter 2025 financial results and corporate update.
Does BioNTech file annual reports under Form 20-F or 40-F?
BioNTech SE indicates it files annual reports under Form 20-F.
What is BioNTech's SIC code?
BioNTech's Standard Industrial Classification (SIC) code is 2836, for Biological Products (No Diagnostic Substances).
Filing Stats: 344 words · 1 min read · ~1 pages · Grade level 13 · Accepted 2025-11-03 06:49:51
Filing Documents
- form6-kq32025earningsprear.htm (6-K) — 16KB
- a99120251103_bntxq32025pre.htm (EX-99.1) — 328KB
- a992bntxq32025presentati.htm (EX-99.2) — 41KB
- a992bntxq32025presentati001.jpg (GRAPHIC) — 63KB
- a992bntxq32025presentati002.jpg (GRAPHIC) — 309KB
- a992bntxq32025presentati003.jpg (GRAPHIC) — 67KB
- a992bntxq32025presentati004.jpg (GRAPHIC) — 68KB
- a992bntxq32025presentati005.jpg (GRAPHIC) — 76KB
- a992bntxq32025presentati006.jpg (GRAPHIC) — 106KB
- a992bntxq32025presentati007.jpg (GRAPHIC) — 136KB
- a992bntxq32025presentati008.jpg (GRAPHIC) — 67KB
- a992bntxq32025presentati009.jpg (GRAPHIC) — 78KB
- a992bntxq32025presentati010.jpg (GRAPHIC) — 137KB
- a992bntxq32025presentati011.jpg (GRAPHIC) — 134KB
- a992bntxq32025presentati012.jpg (GRAPHIC) — 145KB
- a992bntxq32025presentati013.jpg (GRAPHIC) — 127KB
- a992bntxq32025presentati014.jpg (GRAPHIC) — 146KB
- a992bntxq32025presentati015.jpg (GRAPHIC) — 146KB
- a992bntxq32025presentati016.jpg (GRAPHIC) — 106KB
- a992bntxq32025presentati017.jpg (GRAPHIC) — 59KB
- a992bntxq32025presentati018.jpg (GRAPHIC) — 108KB
- a992bntxq32025presentati019.jpg (GRAPHIC) — 144KB
- a992bntxq32025presentati020.jpg (GRAPHIC) — 73KB
- a992bntxq32025presentati021.jpg (GRAPHIC) — 24KB
- a992bntxq32025presentati022.jpg (GRAPHIC) — 85KB
- a992bntxq32025presentati023.jpg (GRAPHIC) — 121KB
- a992bntxq32025presentati024.jpg (GRAPHIC) — 110KB
- a992bntxq32025presentati025.jpg (GRAPHIC) — 187KB
- image_0.jpg (GRAPHIC) — 19KB
- 0001776985-25-000064.txt ( ) — 4304KB
From the Filing
Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a16 OR 15d16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 FOR THE MONTH OF NOVEMBER 2025 COMMISSION FILE NUMBER 001-39081 BioNTech SE (Translation of registrant's name into English) An der Goldgrube 12 D-55131 Mainz Germany +49 6131-9084-0 (Address of principal executive offices) Indicate by check mark whether the registrant files or will file annual reports under cover Form 20F or Form 40F Form 20F Form 40F Indicate by check mark if the registrant is submitting the Form 6K in paper as permitted by Regulation ST Rule 101(b)(1) Indicate by check mark if the registrant is submitting the Form 6K in paper as permitted by Regulation ST Rule 101(b)(7) DOCUMENTS INCLUDED AS PART OF THIS FORM 6-K On November 3, 2025, BioNTech SE (the "Company") issued a press release announcing its third quarter 2025 financial results and corporate update and details of a conference call to be held at 800 am EST on November 3, 2025 to discuss the results. The press release and the conference call presentation are attached as Exhibits 99.1 and 99.2, respectively, and incorporated by reference herein. The information contained in Exhibits 99.1 and 99.2 shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, unless expressly set forth by specific reference in such a filing. SIGNATURE Pursuant to the requirements of the Exchange Act, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. BioNTech SE By s Ramn Zapata-Gomez By s Dr. Sierk Poetting Name Ramn Zapata-Gomez Name Dr. Sierk Poetting Title Chief Financial Officer Title Chief Operating Officer Date November 3, 2025 EXHIBIT INDEX Exhibit Description of Exhibit 99.1 BioNTech Announces Third Quarter 2025 Financial Results and Corporate Update 99.2 Third Quarter 2025 Corporate Update and Financial Results